Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

Individual predictors of increased serum mesothelin in asbestos-exposed workers

verfasst von: Rosa Filiberti, Paola Marroni, Manlio Mencoboni, Virginia Mortara, Pietro Caruso, Alex Cioè, Luigi Michelazzi, Domenico F. Merlo, Andrea Bruzzone, Barbara Bobbio, Lisette Del Corso, Roberto Galli, Paola Taveggia, Guglielmo Dini, Fabio Spigno

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The soluble mesothelin-related peptide (SMRP), a candidate marker for screening of subjects with asbestos exposure, is influenced by some individual and clinical factors. The aim of this study was to quantify the role of age, smoking, weight, presence of diseases and exposure to asbestos on serum SMRP levels in a large series of subjects exposed to asbestos, possible candidates for mesothelioma screening. One thousand seven hundred and four participants underwent clinical examination and were interviewed on medical anamnesis, occupation, smoking and weight. SMRP was measured by an ELISA assay. Overall, median SMRP was 0.4 (IQR 25–75: 0.3–0.7) nmol/l. It was higher in current smokers and in subjects with a cumulative asbestos exposure >50 ff/cc/years than in all the other subjects (p < 0.001 and p = 0.002, respectively). SMRP was positively correlated with age (ρ = 0.11, p < 0.001) and, inversely, with BMI (ρ = −0.15, p < 0.001). SMRP was lower in healthy subjects (n = 1,217: median 0.4 nmol/l) than in subjects with malignant tumors (n = 118: 0.5 nmol/l; p = 0.01), asbestos-related pleural lesions (plaques or thickenings, n = 152: 0.6 nmol/l; p < 0.001) and other benign diseases (n = 182: 0.5 nmol/l; p = 0.04). Multivariate analysis revealed significant predictors of increased SMRP: age >57 years, current smoking, a positive anamnesis for cancer and for asbestos-related pleural lesions, and BMI < 25. Some clinical and demographic variables are associated with serum SMRP levels. The degree of these associations is low, nevertheless they should be accounted for in the interpretation of SMPR as a candidate marker predictive of mesothelioma. The potential predictive value of serum SMRP in screening/surveillance programs must be validated in prospective studies.
Literatur
1.
Zurück zum Zitat Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.PubMedCrossRef Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.PubMedCrossRef
2.
Zurück zum Zitat Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–53.PubMedCrossRef Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–53.PubMedCrossRef
3.
Zurück zum Zitat Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937–42.PubMedCrossRef Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937–42.PubMedCrossRef
4.
Zurück zum Zitat Weber DG, Taeger D, Pesch B, Kraus T, Brüning T, Johnen G. Soluble mesothelin-related peptides (SMRP)—high stability of a potential tumor marker for mesothelioma. Cancer Biomarkers. 2007;3:287–92.PubMed Weber DG, Taeger D, Pesch B, Kraus T, Brüning T, Johnen G. Soluble mesothelin-related peptides (SMRP)—high stability of a potential tumor marker for mesothelioma. Cancer Biomarkers. 2007;3:287–92.PubMed
5.
Zurück zum Zitat Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med. 2010;104:149–56.PubMedCrossRef Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med. 2010;104:149–56.PubMedCrossRef
6.
Zurück zum Zitat Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541–9.PubMedCrossRef Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541–9.PubMedCrossRef
7.
Zurück zum Zitat Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 2009;18:646–50.PubMedCrossRef Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 2009;18:646–50.PubMedCrossRef
8.
Zurück zum Zitat Amati M, Tomasetti M, Mariotti L, Tarquini LM, Valentino M, Santarelli L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res. 2008;655:52–8.PubMedCrossRef Amati M, Tomasetti M, Mariotti L, Tarquini LM, Valentino M, Santarelli L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res. 2008;655:52–8.PubMedCrossRef
9.
Zurück zum Zitat Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011;85:185–92.PubMedCrossRef Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011;85:185–92.PubMedCrossRef
10.
Zurück zum Zitat Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178:832–7.PubMedCrossRef Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178:832–7.PubMedCrossRef
11.
Zurück zum Zitat Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med. 2010;48:869–74.PubMed Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med. 2010;48:869–74.PubMed
12.
Zurück zum Zitat Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest. 2012;141:477–84.PubMedCrossRef Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest. 2012;141:477–84.PubMedCrossRef
13.
Zurück zum Zitat Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010;19:2238–46.PubMedCrossRef Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010;19:2238–46.PubMedCrossRef
14.
Zurück zum Zitat Yang H, Testa J, Carbone M. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol. 2008;9:147–57.PubMedCrossRef Yang H, Testa J, Carbone M. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol. 2008;9:147–57.PubMedCrossRef
15.
Zurück zum Zitat Balmes JR, Daponte A, Cone JE. Asbestos-related disease in custodial and building maintenance workers from a large municipal school district. Ann N Y Acad Sci. 1991;643:540–9.PubMedCrossRef Balmes JR, Daponte A, Cone JE. Asbestos-related disease in custodial and building maintenance workers from a large municipal school district. Ann N Y Acad Sci. 1991;643:540–9.PubMedCrossRef
16.
Zurück zum Zitat Yano E, Tanaka K, Funaki M, Maeda K, Matsunaga C, Yamaoka K. Effect of smoking on pleural thickening in asbestos workers. Br J Ind Med. 1993;50:898–901.PubMed Yano E, Tanaka K, Funaki M, Maeda K, Matsunaga C, Yamaoka K. Effect of smoking on pleural thickening in asbestos workers. Br J Ind Med. 1993;50:898–901.PubMed
17.
Zurück zum Zitat Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquée L, Nackaerts K, Germonpré P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol. 2011;6:889–95.PubMedCrossRef Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquée L, Nackaerts K, Germonpré P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol. 2011;6:889–95.PubMedCrossRef
18.
Zurück zum Zitat Baur X, Czuppon AB. Regulation and compensation of asbestos diseases in Germany. In: Peters GA, Peters BJ, editors. Sourcebook on asbestos diseases, vol 15. Charlottesville: Lexis; 1997. p. 405–19. Baur X, Czuppon AB. Regulation and compensation of asbestos diseases in Germany. In: Peters GA, Peters BJ, editors. Sourcebook on asbestos diseases, vol 15. Charlottesville: Lexis; 1997. p. 405–19.
19.
Zurück zum Zitat BK report Faserjahre. Berufsgenossenschaftliche Hinweise zur Ermittlung der kumulativen Asbestfaserstaub—Dosis am Arbeitsplatz (Faserjahre) und Beurbeitungshinweise zur Berufskrankheit Nr. 4104 BKV (Lungenkrebs). Abridged English version: Report on occupational diseases “fibre/years” 1/1997. Sankt Augustin: Schriftenreihe des Hauptverbandes der gewerbliche Berufsgenossenschaften. 1997. BK report Faserjahre. Berufsgenossenschaftliche Hinweise zur Ermittlung der kumulativen Asbestfaserstaub—Dosis am Arbeitsplatz (Faserjahre) und Beurbeitungshinweise zur Berufskrankheit Nr. 4104 BKV (Lungenkrebs). Abridged English version: Report on occupational diseases “fibre/years” 1/1997. Sankt Augustin: Schriftenreihe des Hauptverbandes der gewerbliche Berufsgenossenschaften. 1997.
21.
Zurück zum Zitat Kauffer E, Vincent R. Occupational exposure to mineral fibres: analysis of results stored on colchic database. Ann Occup Hyg. 2007;51:131–42.PubMedCrossRef Kauffer E, Vincent R. Occupational exposure to mineral fibres: analysis of results stored on colchic database. Ann Occup Hyg. 2007;51:131–42.PubMedCrossRef
22.
Zurück zum Zitat Zajacova A, Dowd JB, Burgard SA. Overweight adults may have the lowest mortality—do they have the best health? Am J Epidemiol. 2011;173:430–7.PubMedCrossRef Zajacova A, Dowd JB, Burgard SA. Overweight adults may have the lowest mortality—do they have the best health? Am J Epidemiol. 2011;173:430–7.PubMedCrossRef
23.
Zurück zum Zitat Whitely E, Ball J. Statistics review 6: nonparametric methods. Crit Care. 2002;6:509–13.CrossRef Whitely E, Ball J. Statistics review 6: nonparametric methods. Crit Care. 2002;6:509–13.CrossRef
24.
Zurück zum Zitat Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8:196–9.PubMedCrossRef Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8:196–9.PubMedCrossRef
25.
Zurück zum Zitat Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888–96.PubMedCrossRef Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888–96.PubMedCrossRef
26.
Zurück zum Zitat Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–42.PubMedCrossRef Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–42.PubMedCrossRef
27.
Zurück zum Zitat van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325–33.PubMedCrossRef van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325–33.PubMedCrossRef
28.
Zurück zum Zitat Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer. 2008;61:235–43.PubMedCrossRef Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer. 2008;61:235–43.PubMedCrossRef
29.
Zurück zum Zitat Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85:265–72.PubMedCrossRef Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85:265–72.PubMedCrossRef
30.
Zurück zum Zitat Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–35.PubMedCrossRef Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–35.PubMedCrossRef
31.
Zurück zum Zitat Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13:5076–81.PubMedCrossRef Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13:5076–81.PubMedCrossRef
32.
Zurück zum Zitat Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2480–7.PubMedCrossRef Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2480–7.PubMedCrossRef
33.
Zurück zum Zitat Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Brüning T, Gube M. Assessment of Confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomarkers Insights. 2010;5:1–8.CrossRef Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Brüning T, Gube M. Assessment of Confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomarkers Insights. 2010;5:1–8.CrossRef
34.
Zurück zum Zitat Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function—analysis of relationship and implications for mesothelioma screening. Lung Cancer. 2011;73:320–4.PubMedCrossRef Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function—analysis of relationship and implications for mesothelioma screening. Lung Cancer. 2011;73:320–4.PubMedCrossRef
35.
Zurück zum Zitat Bañez LL, Hamilton RG, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. J Am Med Assoc. 2007;298:2275–80.CrossRef Bañez LL, Hamilton RG, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. J Am Med Assoc. 2007;298:2275–80.CrossRef
36.
Zurück zum Zitat Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–28.PubMedCrossRef Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–28.PubMedCrossRef
37.
Zurück zum Zitat Frost G, Darnton A, Harding AH. The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain (1971–2005). Ann Occup Hyg. 2011;55:239–47.PubMedCrossRef Frost G, Darnton A, Harding AH. The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain (1971–2005). Ann Occup Hyg. 2011;55:239–47.PubMedCrossRef
38.
Zurück zum Zitat Zitting AJ, Karjalainen A, Impivaara O, Kuusela T, Mäki J, Tossavainen A, Järvisalo J. Radiographic small lung opacities and pleural abnormalities in relation to smoking, urbanization status, and occupational asbestos exposure in Finland. J Occup Environ Med. 1996;38:602–9.PubMedCrossRef Zitting AJ, Karjalainen A, Impivaara O, Kuusela T, Mäki J, Tossavainen A, Järvisalo J. Radiographic small lung opacities and pleural abnormalities in relation to smoking, urbanization status, and occupational asbestos exposure in Finland. J Occup Environ Med. 1996;38:602–9.PubMedCrossRef
39.
Zurück zum Zitat Milara J, Cortijo J. Tobacco, inflammation, and respiratory tract. Cancer Curr Pharm Des. 2012 [Epub ahead of print]. Milara J, Cortijo J. Tobacco, inflammation, and respiratory tract. Cancer Curr Pharm Des. 2012 [Epub ahead of print].
40.
Zurück zum Zitat Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009;180:437–44.PubMedCrossRef Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009;180:437–44.PubMedCrossRef
41.
Zurück zum Zitat Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev. 2008;17:163–70.PubMedCrossRef Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev. 2008;17:163–70.PubMedCrossRef
Metadaten
Titel
Individual predictors of increased serum mesothelin in asbestos-exposed workers
verfasst von
Rosa Filiberti
Paola Marroni
Manlio Mencoboni
Virginia Mortara
Pietro Caruso
Alex Cioè
Luigi Michelazzi
Domenico F. Merlo
Andrea Bruzzone
Barbara Bobbio
Lisette Del Corso
Roberto Galli
Paola Taveggia
Guglielmo Dini
Fabio Spigno
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0422-6

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.